Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: a comprehensive review of Fostair™ and Trimbow™
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgae090 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Katie Foster und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Bath, Bath, BA2 7AY, United Kingdom. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Asthma, Metered Dose Inhalers, Formoterol Fumarate. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Themen: COPD
Abstract (Originalsprache)
The management of asthma and chronic obstructive pulmonary disease (COPD) poses considerable challenges due to the intricate nature of these respiratory conditions. Fostair™ and Trimbow™, two pressurized metered dose inhalers, have emerged as noteworthy therapeutic options for treating both asthma and COPD. Fostair combines an inhaled corticosteroid, specifically beclometasone dipropionate, with a long-acting beta2-agonist, formoterol fumarate dihydrate, offering a dual-action approach to mitigate airway inflammation and bronchoconstriction. Conversely, Trimbow integrates a tri-particulate formulation consisting of beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide, providing a comprehensive strategy to target the pathophysiology of COPD and asthma. Recent clinical trials have underscored Trimbow’s superior efficacy compared with Fostair, particularly in terms of reducing exacerbation rates and enhancing lung function. However, despite their therapeutic promise, both inhalers encounter challenges, including limited generalizability of study findings and a disparity between in vitro and human trial results. This literature review offers an in-depth analysis of Fostair and Trimbow, delving into their mechanisms of action, clinical applications, and outcomes in human studies for asthma and COPD. Additionally, the review discusses the role of combination therapy in managing respiratory diseases and underscores the necessity for further research to address existing knowledge gaps and optimize therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, University of Bath, Bath, BA2 7AY, United Kingdom.
- Respiratory Technology, Woolcock Institute of Medical Research, Sydney, NSW 2037, Australia.
- Faculty of Medicine and Health Sciences, Macquarie Medical School, Macquarie University, Sydney, NSW 2109, Australia.
ORCID-Profile: Chun Yuen Jerry Wong
Zitieren
APA
Foster, K., & Wong, C. Y. J. (2024). Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: a comprehensive review of Fostair™ and Trimbow™. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae090
Vancouver
Foster K, Wong CYJ. Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: a comprehensive review of Fostair™ and Trimbow™. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae090
BibTeX
@article{Foster2024,
author = {Foster, Katie and Wong, Chun Yuen Jerry},
title = {Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: a comprehensive review of Fostair™ and Trimbow™},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgae090}
}
EUVIMED